Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 389

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 389
---
 components of our general and administrative expenses for the periods indicated:

Three Months Ended June 30,Change20252024$% (in thousands, except percentages)Employee-related costs$2,114 $2,054 $60 2.9 %Stock-based compensation expense915 983 (68)(6.9)%Professional fees942 726 216 29.8 %Facilities and other allocated expenses67 61 6 9.8 %Other258 430 (172)(40.0)%Total general and administrative$4,296 $4,254 $42 1.0 %

General and administrative expenses increased by approximately $42 thousand, or 1.0%, to approximately $4.3 million for the three months ended June 30, 2025 compared to approximately $4.3 million for the three months ended June 30, 2024. The increase of approximately $42 thousand was primarily due to $0.2 million increase in professional fees for accounting, auditing and legal services and $0.1 million increase in employee-related costs, offset by decreased stock-based compensation expense of approximately $0.1 million and $0.2 million of other costs.

Amortization of Intangible Asset

Amortization of intangible asset was $7,317 for the three months ended June 30, 2025 and 2024. This amortization is related to the technology acquired for the BioArkive acquisition completed in December 2021.

Other Income (Expense)

Interest income decreased by approximately $0.5 million for the three months ended June 30, 2025 as compared to the three months ended June 30, 2024, driven primarily by lower interest rates and a lower total cash balance.

There was no other income for the three months ended June 30, 2025, compared to $8 thousand for the three months ended June 30, 2024. This was primarily a result of there being no marketable securities as of June 30, 2025 and December 31, 2024, respectively.

Comparison of the Six Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations for the periods indicated:

29

Six Months Ended June 30,Change20252024$%(in thousands, except percentages)Operating expensesResearch and development$21,926$21,854$720.3%General and administrative8,3028,